UAE & GCC Healthcare InsightsWhat we publish, we have lived through on a mandate.
Current thinking on healthcare, life sciences, and capital in the GCC. No trend pieces, no reheated news, just the reads we would give a client working the same decision.
UAE healthcare regulatory & deal tracker Every instrument that changed how deals price, with the primary source for each.
Deal Brief15 October 2026Four Saudi Exchange filings in three days put SAR 258m on public hospital maintenance and IT outsourcing. Only SAR 192m of it is signed, and the largest contract describes its scope two waysWhat four Saudi Exchange disclosures from 13 to 15 October 2026 say about public health buyers outsourcing medical equipment maintenance and IT, what they can and cannot be used for as price evidence, and what a private operator bidding into a Saudi cluster should take from them.Regulatory Brief14 October 2026Dubai has named ten titles its licensed professionals may not use, including Aesthetic Specialist and Smile Specialist. A clinic that sells on them has a diligence problemWhat DHA circular CIR-2026-00000184 requires of Dubai healthcare professionals and facilities on professional titles, which titles it names as not approved, and how a buyer of a Dubai clinic should test whether revenue depends on practitioners marketed beyond their licence.Deal Brief13 October 2026The CCI has cleared Permira's minority secondary in Cloudnine without a price. Apollo's filing already put one on Cloudnine's shares, and that is the number a maternity or fertility seller should readWhat the CCI approval of Permira's Cloudnine secondary does and does not disclose, what Apollo Hospitals' Regulation 30 filing implies about the value of Cloudnine equity, and what an owner of a maternity or fertility business should secure before taking stock in a consolidating platform.
- 9 October 2026Regulatory BriefAbu Dhabi moves its Mandatory Tariff to the 2024 ICD-10-CM and CPT code sets on 1 January 2027. No new prices are published yet, and a 2027 forecast built on today's codes is not yet the revenue the tariff will payWhat DoH Circular USO/204/2026 changes in the Abu Dhabi Mandatory Tariff, what the January 2024 code-set update shows about how DoH reprices, how the SY02-2025 cost-data closure sits beside it, and what a buyer should test in a 2027 provider forecast.
- 9 October 2026Regulatory BriefFrom 1 January 2027, large new hospitals in Abu Dhabi must build underground protected capacity into the design. The engineering standard is due the same day, and the cost is nowhere in the circularWhich new Abu Dhabi hospitals DoH Circular 202/2026 catches, why the cost falls at the design stage, what the pending technical standard leaves open, and how a developer, operator or lender should carry the requirement in a capex case before DoH issues the specification.
- 8 October 2026Deal BriefA listed Saudi dental chain walked away from a three-clinic acquisition on the day its six-month MoU ran out, and licensed two new Riyadh branches of its own in the weeks beforeWhat Basma Adeem's MoU for the Al-Ajaji Dental Complex set out, why its terms left the seller with little to hold, and what a Saudi clinic owner should settle before signing a non-binding MoU with a listed buyer.
- 6 October 2026Deal BriefKIMS is buying equity in hospitals it already runs, and the filings show what an O&M contract converts intoWhat KIMS's four Reg 30 filings of 6 October 2026 disclose about prices for O&M-run hospitals, why the profitable one sold control at once while the loss-makers took minority capital or a staged sale, and why an exclusive O&M fee makes the operator the natural buyer.
- 6 October 2026Regulatory BriefAbu Dhabi writes transplant cover into every Basic, Enhanced and Flexi policy from 1 November 2026, including policies already in force. The member's share is capped. The insurer's is notWhat DoH Circular 197/2026 adds to Abu Dhabi health insurance policies, what members pay and what insurers carry, and how a buyer of an insurance or TPA book should price a benefit that lands mid-term.
- 30 September 2026Regulatory BriefSaudi private hospitals will be paid per case for all admitted insured care from 1 January 2028. The base rate is negotiated, and the evidence for that negotiation is being generated in shadow billing nowWhat CHI's DRG Implementation Guideline v1.0 changes for Saudi private hospital revenue from 2028, why shadow-billing data is the negotiating file, and what a buyer or owner should pull from a hospital before valuing it.
- 29 September 2026Deal BriefIHH plans to take Fortis to 51% while a court-ordered forensic audit examines how it took control in 2018What the Fortis and IHH filings say about the Delhi High Court forensic audit, why a clean primary entry in 2018 did not keep IHH out of it, and how SEBI's 5% creeping limit sets the pace of a move to 51%.
- 25 September 2026Regulatory BriefAbu Dhabi has barred critical health systems from relying on a single cloud provider from 1 January 2027. The circular does not define critical, and the answer is already in a document DoH requires every facility to keepWhat DoH Circular 191/2026 requires of Abu Dhabi providers, payers and health-data vendors, where its undefined word 'critical' will be settled, and what a buyer should put in the deal before 1 January 2027.
- 24 September 2026Regulatory BriefAbu Dhabi hospitals in Phase 1 of DoH's PROMs programme must run a digital outcomes platform integrated with DoH by 1 March 2027. DoH has not published who is in Phase 1, and an owner planning a sale should read the data before a buyer doesWhat DoH Circular 190/2026 requires of Phase 1 facilities, what it leaves unsaid about platforms, sanctions and payment, and what an owner planning a sale should do before 1 March 2027.
- 22 September 2026Regulatory BriefMalaffi's published list of facilities required to connect still puts traditional and complementary medicine centres outside the mandate. DoH Circular 171/2026 brought them inside it, and the price of missing the deadline is the licenceWhat DoH Circular 171/2026 requires of TCAM centres, why the published Malaffi list contradicts it, and what a buyer of a wellness or complementary medicine platform should do before signing.
- 22 September 2026Regulatory BriefSFDA authorised two Saudi AI diagnostic products through its innovative devices pathway. The guidance for that pathway says in terms that it does not shorten the reviewWhat SFDA's Innovative Medical Devices Pathway grants and what it demands, read against the two AI software authorisations announced on 10 September 2026, and what a buyer of a Saudi AI-health company should ask to see.
- 19 September 2026Regulatory BriefAbu Dhabi's managed entry agreements put DoH in the payer's seat for Thiqa and Basic. For an innovative drug, the list price is no longer the revenue lineWhat DOH/Policy/EMEARSAEA/V1 allows DoH to agree with manufacturers of high-cost medicines, who is party to it, and what a buyer of a drug licence, distributor or pharma business should ask to see.
- 17 September 2026Deal BriefAdvent is putting INR 3,150 crore into Yatharth Hospitals for 24.87%. The filings show how a foreign fund holds a large minority in a listed Indian hospital chain without control, and how it gets outWhat the Yatharth filings show about pricing, control, indemnity and exit in a large minority stake in a listed Indian hospital chain, and which terms a GCC investor should put next to its own.
- 14 September 2026Regulatory BriefSFDA approved Frehemgo before the FDA and EMA, which had held Novo Nordisk's filings for a year. The Saudi route it used only admits drugs approved nowhere elseHow SFDA's Breakthrough Medicines Program produced a first-in-world approval for Frehemgo, what its rules mean for launch sequencing and access negotiations, and what a distributor or specialty-pharmacy buyer should re-read.
- 11 September 2026Deal BriefPureHealth's UK lab takeover was a pre-pack out of administration. The release gave no price; the administrators' filing didWhat the UK insolvency record says about PureHealth's takeover of the Unilabs UK laboratories, why the price is not a valuation benchmark, and what a GCC group with an overseas platform should check in its own supply base.
- 7 September 2026Regulatory BriefThe UAE's transplant regulations put an open-ended tail on every health insurer in the country, and gave them six months to price itWhat Cabinet Resolution 61/2026 requires of transplant facilities and of UAE health insurers, and why the phrase about complications regardless of when they are discovered is the provision to read twice.
- 7 September 2026Regulatory BriefDHA re-issued its social media advertising standard in August. It has been in force since October 2022, and most Dubai clinic feeds breach itWhat the DHA Standards for Medical Advertisement Content on Social Media actually prohibit, why a 2026 circular about a 2022 standard is an enforcement signal, and how historic content becomes a licence-level diligence item.
- 7 September 2026Regulatory BriefAbu Dhabi's Emiratisation shortfall does not reset in January. It compounds, and the penalty list ends at the Daman-Thiqa networkWhat DoH Circular 164/2026 does to the workforce line in an Abu Dhabi healthcare operating model, and why an acquired facility's Emiratisation gap is priced as a multi-year liability rather than a one-year fine.
- 7 September 2026Deal BriefThiqa pays for social egg freezing in Abu Dhabi. The eligibility gate is narrow enough to change what a fertility clinic is worthHow the Thiqa social egg freezing policy defines its covered cohort, and what the eligibility gate, the psychological assessment and the five-year storage limit do to the valuation of a UAE assisted-reproduction asset.
- 7 September 2026Regulatory BriefBahrain terminated its traceability hub provider, then built its own. If you place devices on that market, registration opened in AprilWhat NHRA's medical devices and supplies traceability programme requires, who is captured in the first phase, and what the phased design means for a distributor or manufacturer treating Bahrain as a secondary GCC market.
- 7 September 2026Regulatory BriefDubai gives you until 30 January 2027 to appoint a licensed child protection specialist. Abu Dhabi's version has been live since JuneWhat the DHA child protection standard requires of Dubai facilities before 30 January 2027, how the Abu Dhabi policy already in force differs, and what a provider group operating across both has to build.
- 4 September 2026Regulatory BriefAbu Dhabi's Thiqa obesity policy and the daily-oral GLP-1: what a UAE weight-management clinic is actually worthWhat the Thiqa TRP-OMM policy and the DoH Foundayo announcement mean for the valuation of a UAE weight-management or aesthetic clinic running on GLP-1 revenue.
- 4 September 2026Deal BriefGCC listed hospital operators H1 2026: the occupancy number that reprices every private clinic dealThe listed-operator interim comps that reset the negotiating floor for GCC private hospital and clinic transactions in H1 2026.
- 1 September 2026Regulatory BriefAbu Dhabi moves patient booking onto Sahatna by 30 November 2026. The circular names no penalty, and a deal closing near that date still carries the gapWhat DoH Circular 170/2026 moves onto the government-run Sahatna platform, what its silence on sanctions does and does not tell an operator, and how a buyer or seller should handle integration status in a deal completing around 30 November 2026.
- 23 August 2026Regulatory BriefDubai's DHA clinical research standards: trial revenue has a compliance deadline of 1 January 2027What DHA/HRS/MERD/ST-02 does to Dubai clinical-trial sponsors, CROs, and hospitals — and why a deal closing before 1 January 2027 treats it as a covenant, not a breach.
- 22 August 2026Regulatory BriefThe UAE is approving new medicines before the rest of the world. That changes launch sequencing.What two EDE approvals in sixteen days do to filing sequence, UAE revenue timing, and the economics of distribution agreements signed when the UAE was a late-launch market.
- 21 August 2026Regulatory BriefDoH Abu Dhabi's tele-mental health standard: a new licence gateWhat Standard DoH/ST/SCTMHS/HQS/V1/2026 does to the market-entry and diligence line for any Abu Dhabi mental-health target with remote consultation revenue.
- 21 August 2026M&A ReadAbu Dhabi's mental-health capacity doubling: reading a dated demand statement against a new licence gateWhat the 3 August 2026 DoH capacity statement means for a buyer of an Abu Dhabi mental-health platform, read against the licence, Malaffi and AAMEN barriers a target must already clear.
- 20 August 2026Regulatory BriefDoH Abu Dhabi's DME policy V2: home medical equipment, repricedWhat Policy/DME/HPS/V2/2026 does to DME distributors, home-health providers, and DoH-authorised payers in Abu Dhabi — and where the diligence lines move.
- 20 August 2026Regulatory BriefFrom 1 November, every Saudi health insurer must offer a plan with no pre-approval for outpatient care. The Insurance Authority has not published the product terms, and that is where a clinic's revenue risk will moveWhat the Insurance Authority's 20 August directive requires, what today's 60-minute pre-approval rules already say, and what a buyer of a Saudi clinic or polyclinic should ask before 1 November.
- 15 August 2026Regulatory BriefUAE's Ministerial Decision 91 of 2026: transplant capacity is now a fundable expansionHow UAE Ministerial Decision No. 91 of 2026 and the Hayat programme numbers published alongside it reprice transplant capacity for hospital operators, transplant programmes, insurers and investors.
- 12 August 2026Regulatory BriefCDSCO closes the Phase III global-trial shortcut: India-first approvals no longer skip the IND DivisionWhat CDSCO's 10 August 2026 circular on Phase III Global Clinical Trials with Indian subjects means for MNC sponsors, India-based biotech, and the biotech funds valuing India-first approvals.
- 11 August 2026Regulatory BriefDubai Resolution 49: free zones are inside DHA nowWhy operators who built in a Dubai free zone to sit outside DHA are now inside its perimeter, and what Resolution 49/2024 does to a licence in a sale.
- 11 August 2026Regulatory BriefIRDAI's 2026 TPA amendment: what it repricesWhat the 30 July 2026 IRDAI TPA amendment does to the value and the control structure of an Indian third-party administrator.
- 31 July 2026Regulatory BriefUAE EDE's 3PL model: enter pharma distribution without your own warehouseWhat the EDE's 29 July 2026 3PL storage model does to the capex line, the deal thesis, and the entry sequence for anyone chasing a UAE pharmaceutical distribution licence.
- 9 July 2026Regulatory BriefClinical AI in Abu Dhabi now needs a governance fileUnder the DoH Responsible AI Standard, every clinical AI tool a group deploys needs documented explainability, privacy controls, and accountability sign-off.
- 8 July 2026Market AccessUAE family office: DIFC vs ADGM, decided firstHow high-net-worth families should structure a UAE family office and holding vehicles across DIFC and ADGM, and why the framework has to be settled before assets are transferred.
- 8 July 2026Deal BriefDiligence on a hospital group: what moves priceDiligence on a multi-site medical-center network or hospital group is a discipline in itself, and the findings that reprice a deal sit in payer concentration, denial rates, per-facility licence conditions, health-information connectivity, and the new UAE merger-control regime.
- 8 July 2026Regulatory BriefClinical costing: can your ERP reconcile to the EMR?Abu Dhabi's patient-level clinical costing requirement exposes the ERP-to-EMR integration gap most mid-size hospital groups still carry.
- 6 July 2026Strategy BriefAbu Dhabi's advanced-therapy land grabAbu Dhabi's wave of BIO 2026 advanced-therapy partnerships opens a positioning window for provider groups with research infrastructure to become trial sites and centres of excellence.
- 5 July 2026Infrastructure BriefAbu Dhabi's AED 55bn PPP pipeline: position nowAbu Dhabi's AED 55 billion PPP pipeline opens a health-infrastructure opportunity that rewards sponsors who arrive with grounded feasibility and a bankable financial model.
- 4 July 2026Board BriefWhy geopolitical risk is now a GCC board agenda itemHow Red Sea logistics, war-risk exclusions, and force majeure disputes moved geo-risk onto the GCC board agenda.
- 4 July 2026Strategy BriefEntering UAE healthcare: the sequence that worksWhy UAE healthcare entries fail on sequence rather than strategy, and the order that actually works.
- 4 July 2026Deal BriefUAE healthcare M&A: what 2026 buyers pay forThe gap between what sellers think drives a healthcare valuation and what 2026 buyers actually pay a premium for.
- 2 July 2026Deal BriefDaman's A1 is the highest Moody's rating held by any GCC insurer. That ceiling is single-A, and a UAE health insurance target is now measured against itWhat Moody's A1 rating for Daman says about the top of the GCC insurer credit scale, what it was earned on, and how a buyer of a UAE health insurer, TPA or managed-care business should use it.
- 1 July 2026Market AccessGCC expansion: one market is not sixWhy GCC expansion demands country-by-country entry across six markets, disciplined distributor due diligence, and a Saudi strategy that does not assume the UAE approach carries over.
- 1 July 2026Deal BriefFinancing a buy-and-build healthcare platformThe right mix of debt and equity for a scaling hospital or medical-center-group platform depends on its cash generation and its stage, and the GCC's 2026 capital markets now offer sukuk, private equity, and staged structures to match each one.
- 25 June 2026Workforce BriefThe 2027 Emiratisation clock on clinical rolesThe UAE's 2027 rule directing half of the 2% Emiratisation target to clinical roles turns Emiratisation into a workforce-planning problem your group should be solving through 2026.
- 23 June 2026Deal BriefWhat earns a 10x healthcare multipleAmanat's completion of full ownership of Cambridge Health Group at an implied ~10.5x EBITDA on our own arithmetic shows that scale and margin quality, not top-line revenue, are what command the platform multiple.
- 19 June 2026Market AccessUAE pharma manufacturing: a nine-stage buildThe nine-stage path from feasibility to WHO or EU GMP certification for UAE pharmaceutical manufacturing, and why localisation incentives do not shorten the qualification clock.
- 16 June 2026Strategy BriefThe runway before a DFM or ADX listingWhy the premium multiple on a DFM or ADX listing is earned in the 18-to-24-month readiness window, and what an 18-point readiness assessment tests before the transaction begins.
- 13 June 2026Risk BriefForce majeure will not save an unwritten clauseWhy force majeure protection depends on clause scope and notification discipline, and how sanctions exposure can crystallise on contracts signed long before a designation.
- 12 June 2026Regulatory BriefDubai built a new licence line for longevity clinicsDubai's Law No. 17 of 2026 has been in force since 13 June. Article 7(a) prohibits the longevity Activity without an Authority permit across the Emirate, free zones and the DIFC included, with no grandfathering, while the permit conditions themselves have not issued.
- 11 June 2026Operations BriefA high denial rate costs you moreDenial rates of 12-22% against a managed benchmark below 5% are a bigger prize than pricing, and Avior runs revenue cycle as a discipline rather than a reaction.
- 9 June 2026Regulatory BriefEDE drug registration: there is no verification routeHow UAE marketing authorisation actually works under the Emirates Drug Establishment: one standard eCTD route scaled by product class, a separate 90-working-day pricing clock, and no reliance pathway for products approved by the FDA or EMA.
- 5 June 2026Operations BriefWhere the missing margin points wentThe gap between a 4% margin and a 12-18% benchmark is built and lost in service-line economics, pricing and procurement, and Avior recovers it with tracked impact.
- 28 May 2026Market AccessDHA and DoH licensing: sequence before leaseWhy UAE healthcare facility licensing under DHA or DoH must run in strict sequence, and how a stage-two decision determines what happens at stage six.
- 22 May 2026Regulatory BriefThree emirates, three compliance regimes, one calendarA multi-site group across Dubai, Abu Dhabi and Sharjah now carries three renewal calendars, three connectivity mandates and three penalty schedules, and needs one unified compliance spine to govern them.
- 21 May 2026Regulatory BriefSharjah tightened its health rulebook: map your sitesSharjah's 2026 amendment adds administrative penalties across government, private and free-zone facilities and their professionals, so groups with Sharjah sites need a Sharjah-specific policy map and a per-clinician re-credentialing plan.
- 16 May 2026Deal BriefWhy healthcare and pharma M&A is differentWhat separates a healthcare or pharma acquisition from generic M&A, and why the valuation runs longer.
- 12 May 2026Market AccessUAE business setup: free zone, mainland or DIFCWhy the free zone, mainland and DIFC or ADGM decision must be modelled against Corporate Tax and banking at establishment, not treated as paperwork.
- 9 May 2026Deal BriefArada's Reem deal opens a new exit routeA property developer's AED 2 billion commitment to Reem Hospital signals that strategics chasing recurring revenue now sit alongside PE and sovereigns as credible buyers for scalable multi-site healthcare brands.
- 22 April 2026Regulatory BriefUAE merger control hits healthcare dealsThe UAE's new merger-control regime forces pre-closing clearance on many healthcare deals, so regulatory runway and UBO disclosure now belong in the deal timeline.
- 1 April 2026Regulatory BriefAbu Dhabi's revised quality and patient safety policy names insurers on its cover. They have been in scope since 2017. What changed is the dutyWhat DoH/STD/HQS/QPS/V2/2026 changes for Abu Dhabi health insurers against the 2017 version 1.0, and what a buyer of a payer-side business should verify.
- 26 February 2026Regulatory BriefThe end of UAE pharma exclusivityThe end of the exclusive-distributor model in the UAE is an M&A and re-contracting catalyst that favours distributors with cold-chain, hospital and tender infrastructure.
- 18 November 2025Regulatory BriefDubai's claims rulebook now puts your permit at riskDubai's PD-05-2025 rebuilds the claim lifecycle around eClaimLink with hard SLAs and permit-level penalties, forcing hospital and medical-center groups to run revenue cycle natively rather than around the system.
- 3 November 2025Regulatory BriefDay-case DRG in Abu Dhabi: coding now sets marginAbu Dhabi's move to case-based DRG for day-case procedures shifts margin from fee-for-service billing to coding accuracy and resource control.
Subscribe
The UAE healthcare regulatory briefing
What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.
One email a fortnight. Unsubscribe from any of them.